Currently Viewing:
Newsroom
Currently Reading
The Allen Institute for Immunology Plans Long-term Goal of Mapping the Immune System
December 15, 2018 – David Bai, PharmD
Osteoporosis Working Group Creates Recommendations for Economic Evaluations
December 15, 2018 – Allison Inserro
Federal Judge Strikes Down Affordable Care Act
December 15, 2018 – Allison Inserro and Mary Caffrey
Osteoporosis Screening Strategies Don't Identify Younger Women at Risk
December 14, 2018 – Allison Inserro
Study Determines Why Patients With HIV Have Higher Rates of Cancer
December 14, 2018 – Alison Rodriguez
Sofosbuvir-Based Therapy Safe in Patients With HCV and Certain Cancers
December 14, 2018 – Samantha DiGrande
Gender Differences Found in COPD Hospitalizations and In-Hospital Deaths
December 14, 2018 – Alison Rodriguez
Nontuberculous Mycobacterial Lung Disease Doubled the Risk of Death in a Managed Care Population
December 14, 2018 – Jackie Syrop
What We're Reading: Court Trims Birth Control Rule; Guns as Public Health Issue; California Lenient Toward Doctors
December 14, 2018 – AJMC Staff

Study Finds Sustained Efficacy of Botox for Migraine Over 3 Years

Jaime Rosenberg
A new study has indicated that long-term treatment with onabotulinumtoxin A is effective, safe, and well-tolerated in the patient population.
A response rate of 65% is expected after 3 courses of treatment with onabotulinumtoxin A (Botox) in patients with chronic migraine. Now, a new study has indicated that long-term treatment with onabotulinumtoxin A is effective, safe, and well-tolerated in the patient population.

Building off of a previous study demonstrating the short-term efficacy of the treatment, which is given every 3 months, the study researchers assessed onabotulinumtoxin A in patients who responded to the treatment after 3 sessions. The open-label, single-arm, prospective, observational study followed patients at 5 headache centers around Greece.

“We previously reported that 3 courses of onabotulinumtoxin A prophylactic therapy were able to effectively reduce both the mean headache days/month as well as the days with peak headache intensity >4/10, compared to baseline, in a cohort of 81 patients,” wrote the researchers. “A reduced intake of acute headache medications per month was also apparent.”

The 65 patients who had at least a 50% reduction in mean headache days per month after the 3 sessions were followed for 3 years while taking the treatment. The majority (86.1%) remained on the treatment throughout the study period. Among the 9 patients who dropped out, 5 dropped out due to significant improvement and belief that additional sessions were not needed.

To determine the sustained efficacy of the treatment, the researchers studied changes from the trimester after the third cycle of onabotulinumtoxin A (10 to 12 months [T1]) to the trimester after completing 2 years of treatment (25 to 27 months [T2]) and to the trimester after completing 3 years of treatment (37 to 39 months [T3]).

Between T1 and over 3 years of therapy to T3, there was a significant decrease in mean monthly headache days (7.2 vs 3.4). Similarly, the mean number of monthly days with peak migraine intensity of higher than 4 significantly decreased between T1 and T3 (3.4 vs 2.5). These decreases also led to a significant change in the days of acute headache medication use per month during the time period (4.7 vs 2.8).

“Significant changes towards further improvement occurred in all efficacy variables from T2 to T3, thereby supporting the sustained efficacy of onabotulinumtoxin A consistently administered in a long-term basis,” wrote the authors.

The researchers highlighted that no patient became resistant to the treatment, and the safety analysis showed that it was safe and well tolerated, without severe side effects. However, they noted that a few patients experienced transient and mild adverse events, including wheals in the injection site and shoulder and/or neck pain.

Fifty of the 56 patients that completed the 3 years of treatment continued treatment for additional sessions, and the authors plan to publish the results.

Reference:

Vikelis M, Argyriou A, Dermitzakis E, et al. sustained onabotulinumtoxin A therapeutic benefits in patients with chronic migraine over 3 years of treatment [published September 17, 2018]. J Headache Pain. doi: https://doi.org/10.1186/s10194-018-0918-3.

 
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!